About
Andrew Kleiboeker joined RiverVest as an analyst in 2020, was promoted to senior analyst in 2022 and associate in 2024. He supports due diligence on medical device investments and performs financial analysis for portfolio financings and M&A, and holds a board observer seat at InterVene Medical. He earned a B.S. in Business Administration summa cum laude from Washington University in St. Louis.
Colleagues at RiverVest Venture Partners
Alessandro Sette
Scientific Advisor; Professor and Member, La Jolla Institute for Immunology at RiverVest Venture Partners
Andy Craig
Co-founder at RiverVest Venture Partners
Corrin Short
Executive Assistant at RiverVest Venture Partners
Courtney Harris
Controller at RiverVest Venture Partners
Derek Rapp
Investor at RiverVest Venture Partners
Gary DeCrescenzo
Scientific Advisor; Independent Consultant, Pharmaceutical Research and Development at RiverVest Venture Partners
Isaac Zike
Managing Director, Ph.D. at RiverVest Venture Partners
Jared Rutter
Scientific Advisor; Professor of Biochemistry and HHMI Investigator, University of Utah at RiverVest Venture Partners